Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd.

Main purpose: To use the test preparation of relugolix tablets licensed by Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. and produced by Hunan Fangsheng Pharmaceutical Co., Ltd., and the reference preparation of relugolix tablets (trade name: ORGOVYX®) licensed by Accord Healthcare S.L.U., to investigate the pharmacokinetic parameters and relative bioavailability of the two preparations in the fasting and postprandial state, and to evaluate whether the two preparations are bioequivalent. Secondary purpose: To evaluate the safety of the test preparation and reference preparation of relugolix tablets after a single oral administration on an empty stomach/postprandial basis in healthy Chinese male subjects.

To investigate the pharmacokinetic characteristics of a single oral administration of bisoprolol amlodipine tablets [test preparation, specification: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine)] provided by Guangdong Fangsheng Jianmeng Pharmaceutical Co., Ltd. in healthy subjects under fasting and postprandial conditions and a single oral administration of bisoprolol amlodipine tablets [reference preparation, specification: 5 mg bisoprolol fumarate and 5 mg amlodipine besylate (calculated as amlodipine)] certified by Merck Kft under the same conditions, evaluate the bioequivalence and safety of the two preparations, and provide a basis for the registration application of the test preparation.